Citation Impact
Citing Papers
Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data
2020
Characteristics of SARS-CoV-2 and COVID-19
2020 Standout
Rheumatoid arthritis
2016 Standout
Role of Mass Media and Public Health Communications in the COVID-19 Pandemic
2020 Standout
Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19
2020
Preliminary studies on the effectiveness of the novel pulicide, spinosad, for the treatment and control of fleas on dogs
2007
Natural products in crop protection
2009 Standout
Insights from nanomedicine into chloroquine efficacy against COVID-19
2020 Standout
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects
2017
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
2020
The trinity of COVID-19: immunity, inflammation and intervention
2020 Standout
Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis
2020
Tofacitinib versus Methotrexate in Rheumatoid Arthritis
2014
Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study
2017
Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function
2019
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
2020 Standout
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
2020 Standout
Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
2018
Etanercept for the Treatment of Rheumatoid Arthritis
2018
In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
2020 Standout
Industry sponsorship and research outcome
2017 Standout
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19
2020 Standout
Works of M. Boy being referenced
Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
2015
Pharmacokinetics of tofacitinib, a janus kinase inhibitor, in patients with impaired renal function and end‐stage renal disease
2013
Efficacy and safety of selamectin against fleas and heartworms in dogs and cats presented as veterinary patients in North America
2000
Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor
2016
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
2019
AB0595 Changes in serum creatinine in patients with active rheumatoid arthritis treated with TOFACITINIB (CP-690,550)
2012
Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials
2014
Lymphoma in the Tofacitinib Rheumatoid Arthritis Clinical Development Program
2017